These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 16914310)
1. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Kouwenhoven MC; Kros JM; French PJ; Biemond-ter Stege EM; Graveland WJ; Taphoorn MJ; Brandes AA; van den Bent MJ Eur J Cancer; 2006 Oct; 42(15):2499-503. PubMed ID: 16914310 [TBL] [Abstract][Full Text] [Related]
2. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M; J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518 [TBL] [Abstract][Full Text] [Related]
3. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236 [TBL] [Abstract][Full Text] [Related]
4. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Triebels VH; Taphoorn MJ; Brandes AA; Menten J; Frenay M; Tosoni A; Kros JM; Stege EB; Enting RH; Allgeier A; van Heuvel I; van den Bent MJ Neurology; 2004 Sep; 63(5):904-6. PubMed ID: 15365146 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. Ahluwalia MS; Xie H; Dahiya S; Hashemi-Sadraei N; Schiff D; Fisher PG; Chamberlain MC; Pannullo S; Newton HB; Brewer C; Wood L; Prayson R; Elson P; Peereboom DM J Neurooncol; 2015 Mar; 122(1):111-9. PubMed ID: 25534576 [TBL] [Abstract][Full Text] [Related]
6. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687 [TBL] [Abstract][Full Text] [Related]
7. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. van den Bent MJ; Chinot O; Boogerd W; Bravo Marques J; Taphoorn MJ; Kros JM; van der Rijt CC; Vecht CJ; De Beule N; Baron B Ann Oncol; 2003 Apr; 14(4):599-602. PubMed ID: 12649108 [TBL] [Abstract][Full Text] [Related]
8. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Levin N; Lavon I; Zelikovitsh B; Fuchs D; Bokstein F; Fellig Y; Siegal T Cancer; 2006 Apr; 106(8):1759-65. PubMed ID: 16541434 [TBL] [Abstract][Full Text] [Related]
10. Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms. Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; Kopitzki K; du Plessis DG; Prosser J; Vinjamuri S; Warnke PC Br J Cancer; 2006 Nov; 95(10):1424-31. PubMed ID: 17031404 [TBL] [Abstract][Full Text] [Related]
11. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Kaloshi G; Benouaich-Amiel A; Diakite F; Taillibert S; Lejeune J; Laigle-Donadey F; Renard MA; Iraqi W; Idbaih A; Paris S; Capelle L; Duffau H; Cornu P; Simon JM; Mokhtari K; Polivka M; Omuro A; Carpentier A; Sanson M; Delattre JY; Hoang-Xuan K Neurology; 2007 May; 68(21):1831-6. PubMed ID: 17515545 [TBL] [Abstract][Full Text] [Related]
12. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; du Plessis DG; Warnke PC Neurology; 2006 Jun; 66(11):1661-7. PubMed ID: 16769937 [TBL] [Abstract][Full Text] [Related]
13. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. Hoang-Xuan K; Capelle L; Kujas M; Taillibert S; Duffau H; Lejeune J; Polivka M; Crinière E; Marie Y; Mokhtari K; Carpentier AF; Laigle F; Simon JM; Cornu P; Broët P; Sanson M; Delattre JY J Clin Oncol; 2004 Aug; 22(15):3133-8. PubMed ID: 15284265 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911 [TBL] [Abstract][Full Text] [Related]
15. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. Buckner JC; Gesme D; O'Fallon JR; Hammack JE; Stafford S; Brown PD; Hawkins R; Scheithauer BW; Erickson BJ; Levitt R; Shaw EG; Jenkins R J Clin Oncol; 2003 Jan; 21(2):251-5. PubMed ID: 12525516 [TBL] [Abstract][Full Text] [Related]
16. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Jenkinson MD; Smith TS; Joyce KA; Fildes D; Broome J; du Plessis DG; Haylock B; Husband DJ; Warnke PC; Walker C Neuroradiology; 2006 Oct; 48(10):703-13. PubMed ID: 16937145 [TBL] [Abstract][Full Text] [Related]
17. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. Polivka J; Polivka J; Repik T; Rohan V; Hes O; Topolcan O Anticancer Res; 2016 Jan; 36(1):471-6. PubMed ID: 26722084 [TBL] [Abstract][Full Text] [Related]
18. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade. Iwadate Y; Matsutani T; Hara A; Hirono S; Ikegami S; Kobayashi M; Ito D; Kawauchi D; Horiguchi K; Tamiya A; Higuchi Y J Neurooncol; 2019 Jan; 141(1):205-211. PubMed ID: 30565028 [TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Thomas AA; Abrey LE; Terziev R; Raizer J; Martinez NL; Forsyth P; Paleologos N; Matasar M; Sauter CS; Moskowitz C; Nimer SD; DeAngelis LM; Kaley T; Grimm S; Louis DN; Cairncross JG; Panageas KS; Briggs S; Faivre G; Mohile NA; Mehta J; Jonsson P; Chakravarty D; Gao J; Schultz N; Brennan CW; Huse JT; Omuro A Neuro Oncol; 2017 Oct; 19(10):1380-1390. PubMed ID: 28472509 [TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]